Regen BioPharma Inc (RGBP)

[the reaper]

RGBP Has Put Out Two 8K's to Address this Fraudulent Release.
They may pursue Legal Action as well.
https://www.marketwatch.com/investing/Stock/rgbp/SecFilings?subview=secarticle&sid=27408109&guid=13419040&type=8
Item 7.01. Regulation FD Disclosure.



This is Amendment No. 1 to our Form 8-K that we filed with the Securities and Exchange Commission on May 8, 2019 (the “ Prior Form 8-K ”). The purpose of this Amendment No. 1 is to further confirm and expand on the disclosures set forth in the Prior Form 8-K as follows:



• The press release referenced in the Prior Form 8-K and stating that the Company had initiated a reverse merger with Aregen Bioscience Inc. (the “ Press Release ”) is entirely a false and misleading press release that contains serious material factual misrepresentations.


• We have not had, as of this date, any discussions, negotiations, or any dealings with Aregan Bioscience, Inc. or any representatives of that company or any other persons regarding any business combination including, but not limited to, a reverse merger or acquisition.


• We do not know who or why anyone would publish and disseminate such false and misleading statements regarding the Company and its affairs.


• We have no relationship with any of the persons who prepared, published, and disseminated the Press Release.


• We did not participate in the preparation and the dissemination of the Press Release, we were not asked to participate in the preparation and dissemination of the Press Release and we had no basis to believe or anticipate that any such Press Release was being issued, disseminated, and otherwise published.


• We did not authorize that press release and we had no expectation that any such press release was to be published or disseminated by anyone.


• We are entirely appalled by the actions of those who prepared and published the Press Release and we caution our stockholders and others to remain vigilant in disregarding suspicious public statements and other published “press releases” claiming to disclose our affairs unless there is a clear basis to confirm that the statements and press releases have been issued by us.


As appropriate, we may take further action to ensure that our stockholders and the market fully understand that we remain vigilant in upholding and conducting our affairs consistent with best practices and the requirements of the law.